Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement Jan 31, 2023
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules Jan 27, 2023
Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference Jan 17, 2023
Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea Jan 10, 2023
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Jan 04, 2023
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29 Dec 20, 2022
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones Dec 19, 2022
